Merck: EU approves two new indications for Keytruda
(CercleFinance.com) - Merck announces that the European Commission has approved two new indications for Keytruda (pembrolizumab) in gynecological cancers.
The first approval concerns the combination of Keytruda with carboplatin and paclitaxel for the first-line treatment of advanced or recurrent endometrial carcinoma.
The second concerns the combination of Keytruda with chemo-radiotherapy for the treatment of locally advanced cervical cancer (FIGO 2014 stages III-IVA).
These approvals are based on the results of the NRG-GY018 and KEYNOTE-A18 phase 3 trials, and pave the way for the marketing of these treatments in the 27 EU member states.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The first approval concerns the combination of Keytruda with carboplatin and paclitaxel for the first-line treatment of advanced or recurrent endometrial carcinoma.
The second concerns the combination of Keytruda with chemo-radiotherapy for the treatment of locally advanced cervical cancer (FIGO 2014 stages III-IVA).
These approvals are based on the results of the NRG-GY018 and KEYNOTE-A18 phase 3 trials, and pave the way for the marketing of these treatments in the 27 EU member states.
Copyright (c) 2024 CercleFinance.com. All rights reserved.